Management of Middle Ear Effusion
For children with otitis media with effusion (OME) who are not at risk for developmental problems, watchful waiting for 3 months is the recommended initial approach, avoiding antibiotics, antihistamines, decongestants, and corticosteroids. 1, 2
Initial Assessment and Risk Stratification
Document laterality (unilateral vs bilateral), duration of effusion, and severity of associated symptoms at each visit using pneumatic otoscopy as the primary diagnostic method 1, 3
Identify at-risk children who require more aggressive management, including those with:
Confirm diagnosis with tympanometry if pneumatic otoscopy findings are uncertain 1, 4
Management Algorithm for Non-Risk Children
First 3 Months: Watchful Waiting
Observe for 3 months from diagnosis (or from onset if known), as 75-90% of OME cases resolve spontaneously within this timeframe 1, 3
Educate families about the natural history of OME, the need for follow-up, and possible sequelae 2, 4
Re-examine at 3-6 month intervals until effusion resolves, significant hearing loss is identified, or structural abnormalities are suspected 1, 2
After 3 Months: Hearing Assessment
Obtain age-appropriate hearing testing when OME persists for 3 months or longer 1, 3, 2
If hearing is normal: Continue watchful waiting with repeat hearing test in 3-6 months if OME persists 2
If mild hearing loss with bilateral effusions ≥3 months: Offer tympanostomy tube insertion 2
If significant hearing loss at any time: Consider earlier surgical intervention 1, 2
Medications to Avoid
Do not prescribe the following, as they lack long-term efficacy and may cause harm:
Antibiotics - show no long-term benefit for OME resolution and contribute to antimicrobial resistance 1, 2, 4, 5
Antihistamines and decongestants - proven ineffective for OME 1, 2, 4
Intranasal or systemic corticosteroids - not effective for treating OME 2, 4
The evidence is clear that while antibiotics may slightly reduce OME persistence at 3 months compared to no treatment, the effect on hearing is very uncertain and the long-term benefits do not justify routine use 5. A 2023 Cochrane review confirmed this, finding very low-certainty evidence for antibiotic benefit 5.
Surgical Management
Indications for Surgery
Bilateral OME with documented hearing difficulties 2
At-risk children with persistent OME regardless of duration 2, 4
Surgical Approach by Age
For children <4 years old:
- Tympanostomy tubes are the preferred procedure 1, 4
- Adenoidectomy should NOT be performed unless a distinct indication exists (nasal obstruction, chronic adenoiditis) 1
For children ≥4 years old:
- Tympanostomy tubes, adenoidectomy, or both may be recommended 1, 4
- Adenoidectomy reduces future need for ear tubes by approximately 50% 1
Management of At-Risk Children
Evaluate for OME at diagnosis of at-risk condition and at 12-18 months of age if diagnosed earlier 4
Obtain hearing testing promptly without waiting 3 months 1, 3, 2
Consider earlier surgical intervention with tympanostomy tubes 2, 4
Provide concurrent speech/language therapy as needed 1
Consider hearing aids or amplification devices for hearing loss independent of OME 1
Common Pitfalls to Avoid
Prescribing antibiotics routinely - they show only short-term benefits with potential adverse effects including antimicrobial resistance 2, 5
Using antihistamines or decongestants - no proven efficacy and potential for adverse effects 1, 2
Failing to obtain hearing assessment when OME persists beyond 3 months 2
Recommending tympanostomy tubes too early in non-risk children, as most cases resolve spontaneously 2
Performing adenoidectomy alone in children <4 years for OME treatment 1
Performing tonsillectomy or myringotomy alone for OME treatment 1
Special Consideration: Newborn Screening Failures
Document counseling of parents regarding the importance of follow-up when infants fail newborn hearing screening due to OME 4
Ensure hearing is normal when OME resolves and exclude underlying sensorineural hearing loss 4
Note that congenital MEE causing screening failure is more persistent than non-congenital MEE and resolves at lower rates 6